Consider Ethical Questions of 'Designer Babies'
By Elizabeth M. Meade,
The Morning Call
| 03. 10. 2014
A recent
New York Times article (Feb. 25) on a new fertility procedure that involves using the genetic material of three people to create a baby does a very good job of outlining the major ethical challenges posed by the technique.
The procedure is intended to produce children free of certain genetic defects, by replacing the mitochondria of the egg with the mitochondria of a donor who is free of the genetic defect. It could potentially be a godsend to families who risk passing certain catastrophic genetic defects on to their children. But, as The Times article rightly points out, it raises the ethical questions of whether we should be designing our children to be free of whatever we consider to be defects.
"Designer babies," as they are often called, represent both the best and worst of our understanding of parenthood. Several techniques already allow us to prevent passing genetic defects on to the next generation.
For years, fertility clinics have been able to screen embryos for genetic defects before implanting them; in some cases, halting or slowing the prevalence...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...